Literature DB >> 8542328

Acute administration of typical and atypical antipsychotic drugs induces distinctive patterns of Fos expression in the rat forebrain.

W Wan1, D J Ennulat, B M Cohen.   

Abstract

Fos expression in the rat brain was investigated by immunohistochemistry after i.p. administration of single doses of a wide range of typical neuroleptic antipsychotic drugs (including the potent dopamine D2 antagonist haloperidol and the mixed monoamine antagonist chlorpromazine) and atypical antipsychotic drugs (including the weak dopamine D2 antagonists clozapine and thioridazine, the relatively pure D2 antagonist raclopride and the mixed D2 and serotonin S2 antagonist risperidone). For comparison to the effects of the antipsychotic drugs and also because the unique clinical therapeutic effects of clozapine have been attributed to S2 blockade, the S2 antagonist ritanserin was also studied. The single shared effect of all antipsychotic drugs tested was the induction of significantly increased Fos immunoreactivity in the nucleus accumbens (NAc). Fos-positive neurons in the NAc were mostly localized in patches throughout its rostrocaudal extent. Haloperidol, chlorpromazine, raclopride and risperidone all significantly increased Fos expression in the medial and lateral striatum. Fos-positive neurons in the striatum were distributed more lateral than medial and declined from rostral to caudal levels. Haloperidol, thioridazine and risperidone also markedly increased Fos expression in the lateral septum. Distinguishing it from the other neuroleptics, clozapine did not increase Fos expression in the lateral striatum, but induced a significant increase in Fos expression in the prefrontal cortex. Ritanserin did not induce Fos expression in any brain region examined, suggesting that S2 antagonism is not responsible for the effects of antipsychotic drugs observed here. Our results suggest that there are distinctive patterns of Fos expression in the forebrain induced by typical and atypical antipsychotic drugs. Notably, Fos expression in the NAc, as a shared property of all the antipsychotic drugs, may be related to the actions mediating the therapeutic effects of these drugs in the treatment of psychotic disorders. The density of Fos-positive neurons stimulated by antipsychotic drugs in the striatum appeared to be correlated with the relative severity of extrapyramidal side-effects produced by these drugs and may be related to the mechanisms mediating these effects.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8542328     DOI: 10.1016/0006-8993(95)00544-z

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  17 in total

Review 1.  Antipsychotic drugs and neuroplasticity: insights into the treatment and neurobiology of schizophrenia.

Authors:  C Konradi; S Heckers
Journal:  Biol Psychiatry       Date:  2001-11-15       Impact factor: 13.382

Review 2.  Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment.

Authors:  Christine Konradi; Stephan Heckers
Journal:  Pharmacol Ther       Date:  2003-02       Impact factor: 12.310

3.  Testing the validity of c-fos expression profiling to aid the therapeutic classification of psychoactive drugs.

Authors:  B E H Sumner; L A Cruise; D A Slattery; D R Hill; M Shahid; B Henry
Journal:  Psychopharmacology (Berl)       Date:  2003-09-10       Impact factor: 4.530

4.  Probabilistic classification and gambling in patients with schizophrenia receiving medication: comparison of risperidone, olanzapine, clozapine and typical antipsychotics.

Authors:  James I Wasserman; Rebecca J Barry; Lisa Bradford; Nicholas J Delva; Richard J Beninger
Journal:  Psychopharmacology (Berl)       Date:  2012-01-12       Impact factor: 4.530

Review 5.  Regional differences in the action of antipsychotic drugs: implications for cognitive effects in schizophrenic patients.

Authors:  Richard J Beninger; Tyson W Baker; Matthew M Florczynski; Tomek J Banasikowski
Journal:  Neurotox Res       Date:  2010-04-08       Impact factor: 3.911

6.  The effects of ziprasidone on regional c-Fos expression in the rat forebrain.

Authors:  C A Jennings; J E Cluderay; J Gartlon; J Cilia; A Lloyd; D N C Jones; E Southam
Journal:  Psychopharmacology (Berl)       Date:  2005-12-03       Impact factor: 4.530

Review 7.  30 years of dynorphins--new insights on their functions in neuropsychiatric diseases.

Authors:  Christoph Schwarzer
Journal:  Pharmacol Ther       Date:  2009-05-28       Impact factor: 12.310

8.  Haloperidol regulates the state of phosphorylation of ribosomal protein S6 via activation of PKA and phosphorylation of DARPP-32.

Authors:  Emmanuel Valjent; Jesus Bertran-Gonzalez; Heather Bowling; Sébastien Lopez; Emanuela Santini; Miriam Matamales; Alessandra Bonito-Oliva; Denis Hervé; Charles Hoeffer; Eric Klann; Jean-Antoine Girault; Gilberto Fisone
Journal:  Neuropsychopharmacology       Date:  2011-08-03       Impact factor: 7.853

Review 9.  Dopamine and incentive learning: a framework for considering antipsychotic medication effects.

Authors:  Richard J Beninger
Journal:  Neurotox Res       Date:  2006-12       Impact factor: 3.911

Review 10.  Molecular mechanisms underlying synergistic effects of SSRI-antipsychotic augmentation in treatment of negative symptoms in schizophrenia.

Authors:  Yael Chertkow; Orly Weinreb; Moussa B H Youdim; Henry Silver
Journal:  J Neural Transm (Vienna)       Date:  2009-07-04       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.